Literature DB >> 15686666

Melatonin reduces bacterial translocation after intestinal ischemia-reperfusion injury.

P Sileri1, G S Sica, P Gentileschi, M Venza, D Benavoli, T Jarzembowski, A Manzelli, A L Gaspari.   

Abstract

Melatonin, the primary pineal hormone, has been reported to protect from oxidative injury after ischemia-reperfusion (IR). The aim of this study was to evaluate the effects of exogenous melatonin on intestinal integrity, ileal colonization, and bacterial translocation 45-minute after mesenteric IR. Sixteen male ACI rats randomly divided into two groups underwent 45-minutes intestinal ischemia by clamping the superior mesenteric artery. One hour prior to ischemia, study animals (n=8, group A) were treated with melatonin (10 mg/kg IP) while control animals (n=8, group B) received the same volume of saline solution. An additional six animals underwent laparotomy and served as a sham-operated group. Animals were sacrificed 24 hours after reperfusion; peritoneal swabs and biopsies of liver, spleen, lung, mesenteric lymph nodes, cecum, and terminal ileum were obtained for microbiology. The ileum samples were also processed for histopathological evaluation of IR-induced injury. Twenty-four hours after reperfusion bacterial translocation to the peritoneal cavity present in all group B animals was reduced to 37.5% among those that were melatonin-treated (group A; P <.05). Furthermore bacterial translocation to mesenteric lymph nodes, spleen, and liver was significantly lower in group A than group B (P <.05). Although cecal and ileal counts did not differ between the two groups, ileal counts from control animals showed increased colonization. Accordingly, a single injection of exogenous melatonin significantly reduced the intestinal IR injury and prevented bacterial translocation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15686666     DOI: 10.1016/j.transproceed.2004.10.085

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

Review 1.  The effect of antioxidant supplementation on bacterial translocation after intestinal ischemia and reperfusion.

Authors:  A Tassopoulos; A Chalkias; A Papalois; N Iacovidou; T Xanthos
Journal:  Redox Rep       Date:  2016-10-13       Impact factor: 4.412

2.  The effect of melatonin on TNBS-induced colitis.

Authors:  Ahmet Necefli; Burcu Tulumoğlu; Murat Giriş; Umut Barbaros; Mücteba Gündüz; Vakur Olgaç; Recep Güloğlu; Gülçin Toker
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

Review 3.  The role of intestinal microbiota and its metabolites in intestinal and extraintestinal organ injury induced by intestinal ischemia reperfusion injury.

Authors:  Fan Deng; Ze-Bin Lin; Qi-Shun Sun; Yue Min; Yue Zhang; Yu Chen; Wen-Ting Chen; Jing-Juan Hu; Ke-Xuan Liu
Journal:  Int J Biol Sci       Date:  2022-06-13       Impact factor: 10.750

4.  Tempol reduces bacterial translocation after ischemia/reperfusion injury in a rat model of superior mesenteric artery occlusion.

Authors:  Ibrahim Berber; Cagatay Aydin; Nural Cevahir; Cigdem Yenisey; Gulistan Gumrukcu; Goksel Kocbil; Gurkan Tellioglu; Koray Tekin
Journal:  Surg Today       Date:  2009-04-30       Impact factor: 2.549

5.  Intestinal ischemia-reperfusion injury alters purinergic receptor expression in clinically relevant extraintestinal organs.

Authors:  Peter M Milano; Christelle D Douillet; Paul J Riesenman; William P Robinson; Stephanie K Beidler; Ben L Zarzaur; Preston B Rich
Journal:  J Surg Res       Date:  2007-08-03       Impact factor: 2.192

6.  Oxidative stress and ischemia-reperfusion injury in gastrointestinal tract and antioxidant, protective agents.

Authors:  Makoto Sasaki; Takashi Joh
Journal:  J Clin Biochem Nutr       Date:  2007-01       Impact factor: 3.114

Review 7.  Microbiome and intestinal ischemia/reperfusion injury.

Authors:  Yuji Nadatani; Toshio Watanabe; Sunao Shimada; Koji Otani; Tetsuya Tanigawa; Yasuhiro Fujiwara
Journal:  J Clin Biochem Nutr       Date:  2018-05-25       Impact factor: 3.114

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.